Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 3, 2007

Buck Institute and Neurobiological Technologies Converge to Find Huntington's Treatment

  • Neurobiological Technologies and the Buck Institute for Age Research formed a partnership to develop a drug to treat Huntington's disease (HD). The research involves fibroblast growth factor-2 (FGF-2), a naturally occurring protein that reportedly has neuroprotective properties. Buck scientists will now seek to create a form of FGF-2 that can be moved into clinical trials.

    Researchers at the Buck have used FGF-2, in both cell-based and animal models of HD. They report that after being treated with FGF-2, mice with HD showed a 150% increase in new nerve cells, compared to a 30% increase in non-HD mice. Treatment with FGF-2 extended the lifespan of the affected mice by 20%, the Buck team adds. The animals also exhibited improved motor performance, decreased cell death, and a reduction in the amount of toxic aggregates that typically form in the brains of those affected by HD.

    “The fact that FGF-2 has such dramatic effects specifically in HD models and is able to cross the blood-brain barrier shows exciting promise as potential new therapy for HD,” remarks Remy Gross, Buck Institute director of business development.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »